Amarillo partners Intas in interferon-alpha lozenge trials to treat influenza in India

Published: 12-Oct-2009
Regulatory Research & Development

Texan biotech Amarillo Biosciences has agreed to a strategic partnership with Intas Pharmaceuticals of India, whereby Intas will sponsor clinical trials of Amarillo's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay Amarillo a royalty on net sales after marketing approval is obtained in India.


Texan biotech Amarillo Biosciences has agreed to a strategic partnership with Intas Pharmaceuticals of India, whereby Intas will sponsor clinical trials of Amarillo's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay Amarillo a royalty on net sales after marketing approval is obtained in India.

The objective of clinical trials in India is to determine the efficacy of low-dose oral interferon in reducing the severity of infection with influenza viruses such as H1N1.

Amarillo has been conducting studies on the drug to treat and prevent respiratory tract disease in animals and has found it to be safe and effective for cats, cattle and horses.

Amarillo's double-blind, placebo-controlled Phase II trial on human volunteers in Perth, Western Australia, is expected to show that the orally administered interferon lozenges can safely reduce the infection rate and severity of symptoms. The results of the study will be released before the end of the year.

"Influenza viruses mutate to evade the effects of anti-viral drugs," said Dr Joseph Cummins, chief executive of Amarillo. "Influenza viruses do not mutate to evade interferon, but instead they have a strategy to sabotage the host interferon system. By giving people interferon orally, we believe we can overcome this viral strategy."

  • Companies:
  • Intas
See more

You may also like

Research & Development

Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research

Read more
The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  3. Precise and efficient VARIO diaphragm pumps from Vacuubrand Advanced vacuum control for reproducible processes
  4. Bio-Courier: a new delivery technology to increase the global accessibility of RNA therapeutics Although lipid nanoparticles (LNPs) are a key delivery technology for nucleic acid therapeutics, their wider clinical translation is hindered by the recognised limitations of current manufacturing protocols
  5. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research

The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Manufacturing

Precise and efficient VARIO diaphragm pumps from Vacuubrand

Advanced vacuum control for reproducible processes
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain

With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
Manufacturing

Isopod rapid cleanrooms helping life science start-ups and smaller businesses grow

The Guardtech Group’s quick-assembly pods provide a fast, high-quality cleanroom solution
Subscribe now